Real-World test of automated insulin system aims to improve blood sugar control for type 1 diabetes

NCT ID NCT07696039

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tracks 300 adults with type 1 diabetes who use the Omnipod 5, an automated insulin delivery system, as part of their routine care. Researchers will compare blood sugar control—measured by time in target range and HbA1c levels—before starting the system and at 6, 12, and 18 months after. The goal is to see if the device improves glucose management in real-world conditions outside of a controlled research setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Omnipod 5 Automated Insulin Delivery System
What this could lead to
If successful, this study could confirm that the Omnipod 5 system helps adults with type 1 diabetes maintain better blood sugar control in real-world settings.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors other than the device. The findings depend on data from a single center and may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • ASST Papa Giovanni XXIII Bergamo

    Bergamo, Italy, 20126, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.